Bio-Thera Solutions, Ltd. (SHA:688177)

China · Delayed Price · Currency is CNY

17.11

+0.03 (0.18%)

At close: Jul 31, 2026

-44.93% (1Y)

Market Cap	7.08B -44.9%
Revenue (ttm)	980.25M +24.4%
Net Income	-390.44M
EPS	-0.94
Shares Out	414.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,858,005
Open	17.18
Previous Close	17.08
Day's Range	17.07 - 17.50
52-Week Range	15.57 - 36.32
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epitheli... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2003

Employees 1,426

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688177

Full Company Profile

Financial Performance

In 2025, Bio-Thera Solutions's revenue was 935.22 million, an increase of 25.84% compared to the previous year's 743.17 million. Losses were -331.94 million, -34.95% less than in 2024.

Financial Statements